Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Lyra Therapeutics Inc (LYRA)

Lyra Therapeutics Inc (LYRA)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 101,928
  • Shares Outstanding, K 13,001
  • Annual Sales, $ 0 K
  • Annual Income, $ -22,130 K
  • 60-Month Beta 0.45
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 1.80
Trade LYRA with:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/21
See More
  • Average Estimate -0.71
  • Number of Estimates 2
  • High Estimate -0.65
  • Low Estimate -0.78
  • Prior Year -0.49
  • Growth Rate Est. (year over year) -44.90%

Price Performance

See More
Period Period Low Period High Performance
1-Month
7.31 +7.25%
on 10/12/21
9.98 -21.44%
on 09/24/21
-0.95 (-10.81%)
since 09/22/21
3-Month
5.83 +34.48%
on 08/03/21
9.98 -21.44%
on 09/24/21
+0.75 (+10.58%)
since 07/22/21
52-Week
5.83 +34.48%
on 08/03/21
16.50 -52.48%
on 03/01/21
-4.35 (-35.68%)
since 10/22/20

Most Recent Stories

More News
Lyra Therapeutics to Highlight LYR-210 and LYR-220 Clinical Programs at Virtual Event with Leading Clinical CRS Experts

/PRNewswire/ -- Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage therapeutics company leveraging its proprietary XTreo™ platform to enable precise,...

LYRA : 7.84 (-1.26%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Sell with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Lyra Therapeutics Inc. is a clinical-stage therapeutics company. It is focused on the development and commercialization of novel integrated drug and delivery solutions for patients with ear, nose and throat diseases. The company's proprietary technology platform, XTreo(TM), is designed to precisely and...

See More

Key Turning Points

3rd Resistance Point 8.39
2nd Resistance Point 8.21
1st Resistance Point 8.03
Last Price 7.84
1st Support Level 7.67
2nd Support Level 7.49
3rd Support Level 7.31

See More

52-Week High 16.50
Fibonacci 61.8% 12.42
Fibonacci 50% 11.16
Fibonacci 38.2% 9.91
Last Price 7.84
52-Week Low 5.83

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar